116 related articles for article (PubMed ID: 35582767)
1. Clinical significance of ERBB2 S310F mutation in extramammary Paget's disease.
Kusaba Y; Kajihara I; Myangat TM; Tanaka K; Kanemaru H; Sawamura S; Makino K; Aoi J; Masuguchi S; Fukushima S
J Dermatol; 2022 Sep; 49(9):e305-e306. PubMed ID: 35582767
[No Abstract] [Full Text] [Related]
2. Treatment of metastatic extramammary Paget's disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F.
Vornicova O; Hershkovitz D; Yablonski-Peretz T; Ben-Itzhak O; Keidar Z; Bar-Sela G
Oncologist; 2014 Sep; 19(9):1006-7. PubMed ID: 25085898
[TBL] [Abstract][Full Text] [Related]
3. Extramammary Paget's disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies.
Maeda T; Kitamura S; Nishihara H; Yanagi T
Oncogene; 2020 Sep; 39(36):5867-5875. PubMed ID: 32724160
[TBL] [Abstract][Full Text] [Related]
4. erbB-2 overexpression but no activation of beta-Catenin gene in extramammary Paget's disease.
Takata M; Fujimoto A; Aoki H; Hatta N; Ooi A; Takehara K
J Invest Dermatol; 1999 Aug; 113(2):258-62. PubMed ID: 10469313
[TBL] [Abstract][Full Text] [Related]
5. Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2
Nordmann TM; Messerli-Odermatt O; Meier L; Micaletto S; Coppetti T; Nägeli M; Kamarachev J; Kudura K; Freiberger SN; Rordorf T; Mangana J; Braun R; Dummer R
Oncotarget; 2019 Nov; 10(62):6647-6650. PubMed ID: 31803359
[TBL] [Abstract][Full Text] [Related]
6. Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease.
Watanabe S; Takeda M; Takahama T; Iwasa T; Tsurutani J; Tanizaki J; Shimizu T; Sakai K; Wada Y; Isogai N; Nishio K; Nakagawa K
Invest New Drugs; 2016 Jun; 34(3):394-6. PubMed ID: 26856856
[TBL] [Abstract][Full Text] [Related]
7. [Expression status of HER2 in mammary and extramammary Paget's disease].
Meng H; Zheng XY; Zhang L; Li WC
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):255-6. PubMed ID: 21616001
[No Abstract] [Full Text] [Related]
8. Experiences of trastuzumab plus paclitaxel combination therapy in metastatic human epidermal growth factor receptor 2-positive extramammary Paget's disease: Four cases and a review.
Sekiguchi N; Kubota S; Noguchi T; Fukushima T; Kobayashi T; Kanda S; Koizumi T; Miyake T; Shirai T; Okuyama R
J Dermatol; 2020 Nov; 47(11):1276-1279. PubMed ID: 32706146
[TBL] [Abstract][Full Text] [Related]
9. c-erbB-2 oncoprotein expression in mammary and extramammary Paget's disease: an immunohistochemical study.
Keatings L; Sinclair J; Wright C; Corbett IP; Watchorn C; Hennessy C; Angus B; Lennard T; Horne CH
Histopathology; 1990 Sep; 17(3):243-7. PubMed ID: 2173676
[TBL] [Abstract][Full Text] [Related]
10. The role of HER-2/neu oncogene and vimentin filaments in the production of the Paget's phenotype.
Hanna W; Alowami S; Malik A
Breast J; 2003; 9(6):485-90. PubMed ID: 14616943
[TBL] [Abstract][Full Text] [Related]
11. Expression of c-erbB-2 oncoprotein in mammary and extramammary Paget's disease.
Wolber RA; Dupuis BA; Wick MR
Am J Clin Pathol; 1991 Aug; 96(2):243-7. PubMed ID: 1713741
[TBL] [Abstract][Full Text] [Related]
12. Loss of Wnt-5α is associated with an invasive phenotype of extramammary Paget's disease.
Xie L; Hayashida S; Furue M
J Cutan Pathol; 2011 Jul; 38(7):576-80. PubMed ID: 21352264
[TBL] [Abstract][Full Text] [Related]
13. Mammary and extramammary Paget's disease.
Sitakalin C; Ackerman AB
Am J Dermatopathol; 1985 Aug; 7(4):335-40. PubMed ID: 3026195
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical study of c-erbB-2 oncoprotein expression in extramammary Paget's disease.
Nishi M; Yoshida H; Setoyama M; Tashiro M
Dermatology; 1994; 188(2):100-2. PubMed ID: 7907892
[TBL] [Abstract][Full Text] [Related]
15. HER2 oncogene amplification in extramammary Paget's disease.
Tanskanen M; Jahkola T; Asko-Seljavaara S; Jalkanen J; Isola J
Histopathology; 2003 Jun; 42(6):575-9. PubMed ID: 12786893
[TBL] [Abstract][Full Text] [Related]
16. High Risk of Proximal and Local Neoplasms in 2206 Patients With Anogenital Extramammary Paget's Disease.
Lee GC; Kunitake H; Stafford C; Bordeianou LG; Francone TD; Ricciardi R
Dis Colon Rectum; 2019 Nov; 62(11):1283-1293. PubMed ID: 31567917
[TBL] [Abstract][Full Text] [Related]
17. Human epidermal growth factor receptor 2 expression in extramammary Paget's disease and mammary Paget's disease.
Jeong SH; Hyeong JH; Park EJ; Kim KJ; Kim KH
Australas J Dermatol; 2022 Feb; 63(1):115-118. PubMed ID: 34964488
[No Abstract] [Full Text] [Related]
18. Assessment of the methods used to detect HER2-positive advanced extramammary Paget's disease.
Hirai I; Tanese K; Nakamura Y; Otsuka A; Fujisawa Y; Yamamoto Y; Hata H; Fujimura T; Matsushita S; Yoshino K; Kameyama K; Amagai M; Funakoshi T
Med Oncol; 2018 May; 35(6):92. PubMed ID: 29744813
[TBL] [Abstract][Full Text] [Related]
19. Extramammary Paget's disease in two siblings.
Demitsu T; Gonda K; Tanita M; Takahira K; Inoue T; Okada O; Yoneda K; Manabe M
Br J Dermatol; 1999 Nov; 141(5):951-3. PubMed ID: 10583201
[No Abstract] [Full Text] [Related]
20. A case of triple extramammary Paget's disease.
Koseki S; Mitsuhashi Y; Yoshikawa K; Kondo S
J Dermatol; 1997 Aug; 24(8):535-8. PubMed ID: 9301148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
